Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Adverse reactions
- 09 Oct 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.
- 02 Jun 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Aug 2019.